Katakura  Industries  Co.,Ltd. Logo

Katakura Industries Co.,Ltd.

Diversified company in real estate, pharmaceuticals, machinery, and textiles.

3001 | T

Overview

Corporate Details

ISIN(s):
JP3211400001
LEI:
Country:
Japan
Address:
中央区明石町6番4号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Katakura Industries Co., Ltd. is a diversified company with operations spanning multiple sectors. The company's core business segments include Real Estate, Pharmaceuticals, Machinery, and Textiles. In real estate, its activities involve the management of commercial facilities, leasing of properties, and the development and utilization of company-owned land. The pharmaceutical division manufactures and sells medications, with a focus on treatments for cardiovascular illnesses such as angina pectoris and cardiac infarction. Additionally, the company engages in the manufacture and sale of mechanical equipment and maintains its legacy operations in the textile industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 04:45
Interim / Quarterly Report
確認書
Japanese 8.7 KB
2025-08-13 04:43
Interim / Quarterly Report
半期報告書-第117期(2025/01/01-2025/12/31)
Japanese 246.8 KB
2025-06-11 09:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.4 KB
2025-04-03 09:00
AGM Information
臨時報告書
Japanese 23.6 KB
2025-03-28 05:22
Governance Information
内部統制報告書-第116期(2024/01/01-2024/12/31)
Japanese 23.3 KB
2025-03-28 05:18
Registration Form
確認書
Japanese 8.7 KB
2025-03-28 05:16
Annual Report
有価証券報告書-第116期(2024/01/01-2024/12/31)
Japanese 1.3 MB
2024-09-11 09:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.4 KB
2024-08-09 08:40
Interim / Quarterly Report
確認書
Japanese 8.7 KB
2024-08-09 08:38
Interim / Quarterly Report
半期報告書-第116期(2024/01/01-2024/12/31)
Japanese 254.9 KB
2024-05-14 08:47
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-05-14 08:45
Quarterly Report
四半期報告書-第116期第1四半期(2024/01/01-2024/03/31)
Japanese 192.4 KB
2024-04-03 09:09
AGM Information
臨時報告書
Japanese 30.7 KB
2024-03-28 05:36
Governance Information
内部統制報告書-第115期(2023/01/01-2023/12/31)
Japanese 23.0 KB
2024-03-28 05:33
Registration Form
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Katakura Industries Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Katakura Industries Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Katakura Industries Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.